FindTrial
Sign In

Population pharmacokinetics of meropenem in patients with end-stage liver disease

Population pharmacokinetics of meropenem in patients with end-stage liver disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036638
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage of liver disease

Interventions

1:Anti infection with meropenem

Sponsors

Shanghai Public Health Clinical Center, Fudan University, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a. Informed consent signed by myself or family members; b. Diagnosis of ESLD (including decompensated cirrhosis, chronic liver failure, chronic and acute liver failure); c. Anti infection with meropenem; d. Aged > 18 years and < 75 years.

Exclusion criteria

Exclusion criteria: a. Allergy to meropenem; b. Received hemodialysis, plasma exchange and other blood purification treatment; c. The vital signs are not stable and the specimen can not be taken; d. Severe renal insufficiency; e. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Meropenem plasma concentration;—

Countries

China

Contacts

Public ContactZhang Yuyi

Shanghai Public Health Clinical Center, Fudan University, Shanghai

zhangyuyi@shphc.org.cn+86 13916609503

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026